Lung Cancer EGFR: What Are The Latest Advanced Treatments in 2023? Insights from Ravi Salgia MD - Synopsis below extracted from the video transcript.
Urothelial Cancer: What’s New in 2023? [Slides] Targeted and Novel Therapies Nataliya Mar MD - Synopsis below extracted from the video transcript.
Lung Cancer EGFR: What Are The Latest Advanced Treatments in 2023? Insights from Ravi Salgia MD - Synopsis below extracted from the video transcript.
Gastrointestinal Malignancies Research Advancements: Insights from Farshid Dayyani, MD - Synopsis below extracted from the video transcript.
Health Inequity Examining and Uncovering Disparities in Healthcare Dr. Hala Borno - Synopsis below extracted from the video transcript.
Poster discussed by Anna Odell, City of Hope - Friends of Cancer Research - Dr. Monty Pal served as a guide and advisory mentor.
In this poster, Anna Odell discusses the studies for treating RCC. "Evaluation of eligibility criteria in contemporary renal cell cancer trials based on ASCO-FCR recommendations.". She emphasizes the need of carefully choosing patients for clinical trials based on the specific molecular and genetic qualities they possess, and she describes the many types of RCC, including papillary and clear cell RCC.
Poster discussed by Ishann Sehgal, City of Hope - Friends of Cancer Research - Dr. Monty Pal served as a guide and advisory mentor.
Ishann Sehgal addresses the eligibility requirements for clinical trials involving renal cell carcinoma (RCC) in this video. He also covers the advancements that ASCO and FCR have made in the treatment of RCC.
According to Ishann, the qualifying standards for RCC clinical research have traditionally been quite stringent. This has the potential to restrict patient involvement and affect the findings of the study. Both the ASCO and the FCR have revised their qualifying requirements in order to accommodate a greater number of patients.
HER2 Low Breast Cancer: What Are the Latest Advancements in Novel Drug Antibody Conjugates for 2023? Yuan Yuan, MD - Synopsis below extracted from the video transcript
Recent developments in our profession, including antibody drug conjugates notably Trastuzumab Deruxtecan, a monoclonal antibody in HER2 low illness, have significantly altered our perception of breast cancer. We previously classified breast cancer as triple-negative, HER2-positive, and ER positive. Now the HER2 low has eliminated the old barrier and put them into the non-HER2 low category, which is really exciting.
What is Belzutifan? 2023 [Slides] Kidney Cancer Breakthroughs Rana McKay, MD - Synopsis below extracted from the video transcript